

# Immunization Update

To access the most up-to-date information about AAFP vaccine schedules or policies, visit [AAFP.org/vaccines](https://www.aafp.org/vaccines).



# Leveraging Our Organizational Strengths

*Reviewing the data.  
Confirming the evidence.  
Creating guidance that matters.*

Science Reviews  
Clinical Guidance  
AAFP Schedules  
Immunization Policy

## Science



## Advocacy



*Collaborating with peers.  
Voicing support & concerns.  
Ensuring access.*

Letters & Statements  
ACIP testimony  
Vaccine Integrity Project  
State support (CA, PA)  
Amicus Activity

AAFP.org/vaccines  
Social Media  
Traditional Media

*Powerful storytelling.  
Dispelling myths.  
Shaping the narrative.*

## Communication



## Education




FPM Supplements  
CME lectures  
Inside FM Podcast

*Advancing FP knowledge.  
Integrating into practice.  
Improving quality (↓ disparities).*



# Our Governance Structure



- Health of the Public staff support this process at every stage.
- Inputs from **external liaisons** are shared at the appropriate level for consideration.
- Members complete annual COI. COI reviewed at each Commission & BOD meeting.
- All policies reviewed q5y. Immunization recommendations updated annually.

# AAFP 2026-27 Schedule release

- 2026 AAFP Vaccine Schedules (March 2026)
  - Other professional society support: IDSA, ACP

## Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger United States 2026

Vaccines and Other Immunizing Agents in the Child and Adolescent Immunization Schedule\*

Monoclonal antibody	Abbreviation(s)	Trade name(s)
Respiratory syncytial virus monoclonal antibody (nirsevimab or clesrovimab)	RSVnAb	Befortus™   Entoria™
Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine	1vCOVmRNA	Comirnaty®/Pfizer-BioNTech COVID-19 Vaccine Spikevax®/Moderna COVID-19 Vaccine, mNexspeek®/Moderna COVID-19 Vaccine Nuvaxovid™/Novavax COVID-19 Vaccine
	1vCOVaPS	Dengvaxia®
Dengue vaccine	DEH4CYD	
Diphtheria, tetanus, and acellular pertussis vaccine	DtaP	Daptacel®   Infanrix®
Haemophilus influenzae type b vaccine	Hib (PRP-T) Hib (PRP-OMP)	ActHib® Hiberix® PedvaxiHB®
Hepatitis A vaccine	HepA	Havrix®   Vagta®
Hepatitis B vaccine	HepB	Engerix-B®   Heplisav-B®   Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated; egg-based)	IV3	Multiple
Influenza vaccine (live, attenuated)	LAIV3	FluLaval®
Influenza vaccine (inactivated; cell culture-based)	ccIV3	Flucelex®
Influenza vaccine (recombinant)	RIV3	Flublok®
Measles, mumps and rubella vaccine	MMR	MM-R II®   Priorix®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-CRM MenACWY-TT	Menveo® MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero® Trumenb®
Meningococcal serogroups A, B, C, W, Y vaccine	MenACWY-TT/MenB-FHbp MenACWY-CRM/MenB-4C	Penbraya™ Penmenvay
Mpxv vaccine	Mpxv	Jynneos®
Pneumococcal conjugate vaccine	PCV15 PCV20	Vaxneuvance™ Prevnar 20®
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23®
Poliovirus vaccine (inactivated)	IPV	IPOL®
Respiratory syncytial virus vaccine	RSV	Abrysvo™
Rotavirus vaccine	RV1 RV2	Rotarix® RotaTeq®
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel®   Boostrix®
Tetanus and diphtheria vaccine	Td	Teniva® Tdax™
Varicella vaccine	VAR	Varivax®
Combination vaccines (use combination vaccines instead of separate injections when appropriate)		
DtaP, hepatitis B, and inactivated poliovirus vaccine	DtaP-HepB-IPV	Pediaris®
DtaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine	DtaP-IPV/Hib	Perinatec®
DtaP and inactivated poliovirus vaccine	DtaP-IPV	Kenix®   Quatracel®
DtaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine	DtaP-IPV/Hib-HepB	Vaxivax®
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad®

### How to use the child and adolescent immunization schedule

- 1 Determine recommended vaccine by age (Table 1)
- 2 Determine recommended interval for catch-up vaccination (Table 2)
- 3 Assess need for additional recommended vaccines by medical condition or other indication (Table 3)
- 4 Review vaccine types, frequencies, intervals and considerations for special situations (Notes)
- 5 Review contraindications and precautions for vaccine types (Appendix)
- 6 Review new or updated guidance (Addendum)

**Report**  
 • Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department  
 • Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or 800-822-7967

For immunization resources and updates to the vaccine schedule, visit [aafp.org/vaccines](http://aafp.org/vaccines) or scan this QR code.



\*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not recommended, it is not listed.

## Recommended Adult Immunization Schedule for Ages 19 Years or Older United States 2026

Vaccines in the Adult Immunization Schedule\*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine	1vCOVmRNA	Comirnaty®/Pfizer-BioNTech COVID-19 Vaccine Spikevax®/Moderna COVID-19 Vaccine   mNexspeek®/Moderna COVID-19 Vaccine Nuvaxovid™/Novavax COVID-19 Vaccine
	1vCOVaPS	
Haemophilus influenzae type b vaccine	Hib	ActHib® Hiberix® PedvaxiHB®
Hepatitis A vaccine	HepA	Havrix®   Vagta®
Hepatitis A and Hepatitis B vaccine	HepA-HepB	Twinnx
Hepatitis B vaccine	HepB	Engerix-B®   Heplisav-B®   Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated; egg-based)	IV3	Multiple
Influenza vaccine (inactivated; cell culture-based)	ccIV3	Flucelex®
Influenza vaccine (recombinant)	RIV3	Flublok®
Influenza vaccine (live, attenuated)	LAIV3	FluMist®
Measles, mumps, and rubella vaccine	MMR	MM-R II®   Priorix®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-CRM MenACWY-TT	Menveo® MenQuadfi®
	MenB-4C MenB-FHbp	Bexsero® Trumenb®
Meningococcal serogroup B vaccine	MenB-FHbp	Trumenb®
Meningococcal serogroups A, B, C, W, Y vaccine	MenACWY-TT/MenB-FHbp MenACWY-CRM/MenB-4C	Penbraya™ Penmenvay
Mpxv vaccine	Mpxv	Jynneos®
Pneumococcal conjugate vaccine	PCV15 PCV20 PCV21	Vaxneuvance™ Prevnar 20® Capvaxine®
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23®
Poliovirus vaccine (inactivated)	IPV	IPOL®
Respiratory syncytial virus vaccine	RSV	Abrysvo™ Abrysvo™ mResvia®
Tetanus and diphtheria vaccine	Td	Teniva®
Tetanus, diphtheria and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Varicella vaccine	VAR	Varivax®
Zoster vaccine (recombinant)	RZV	Shingrix®

### How to use the adult immunization schedule

- 1 Determine recommended vaccinations by age (Table 1)
- 2 Assess need for additional recommended vaccinations by medical condition or other indication (Table 2)
- 3 Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- 4 Review contraindications and precautions for vaccine types (Appendix)
- 5 Review new or updated guidance (Addendum)

**Report**  
 • Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department  
 • Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or 800-822-7967

For immunization resources and updates to the vaccine schedule, visit [aafp.org/vaccines](http://aafp.org/vaccines) or scan this QR code.



\* is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. The use not imply endorsement by the AAFP.

**AAFP.org/vaccines**



# AMA/VIP Evidence Review Panels

- Upcoming Meetings (On-going; now monthly)


- COVID
  - Influenza
  - RSV
  - HPV
  - PCV 21
- 26-27 Fall Respiratory Season Guidance
- AAFP Vaccine Schedule Update

- There are new reviews coming. Possibly meningococcal. Maternal vaccines. Maybe co-administration.

- New vaccine: Lyme disease

- *A new Lyme disease vaccine candidate, LB6V (developed by Pfizer and Valneva), is in Phase 3 trials and showed over 70% efficacy in 2026 results. The vaccine targets the outer surface protein A (OspA) of the bacteria, with plans to submit for FDA approval in 2026, aiming for a potential launch as early as 2027.*

# AAFP 2026-27 Viral Respiratory Season Timeline



# National Adult and Influenza Immunization Summit (NAIIS)

- Meeting May 19-21, 2026
- AAFP Presenting on main stage panel on professional society policy & response to the current environment